AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
Merck KGaA’s oncology catalyst approaches
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
